Search Results

Your Medication Information.

Subjects: *SUICIDAL ideation; *CLOZAPINE; *DRUG interactions

• Source: Brown University Psychopharmacology Update. Sep2022, Vol. 33 Issue 9, p9-10. 2p.

Record details

Higher doses of antipsychotics do not decrease odds of relapse.

Subjects: *DRUG side effects; *DISEASE relapse; *ANTIPSYCHOTIC agents

• Source: Brown University Psychopharmacology Update. Dec2021, Vol. 32 Issue 12, p1-3. 3p.

Record details

Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.

• Authors : Suzuki, Hidenobu¹; Hibino, Hiroyuki²; Inoue, Yuichi³

Subjects: *RETROSPECTIVE studies; *CONTINUUM of care; *DESCRIPTIVE statistics

• Source: Psychogeriatrics. Nov2021, Vol. 21 Issue 6, p950-951. 2p. 1 Graph.

Record details

Olanzapine‐samidorphan combination for schizophrenia lowers weight gain.

Subjects: *COMBINATION drug therapy; *CLINICAL trials; *DRUG side effects

• Source: Brown University Psychopharmacology Update. Dec2020, Vol. 31 Issue 12, p6-7. 2p.

Record details

New treatments emerging for people with serious mental illness.

Subjects: *DRUG approval; *EVALUATION of medical care; *NARCOTIC antagonistsUNITED States. Food & Drug Administration

• Source: Mental Health Weekly. 10/25/2021, Vol. 31 Issue 41, p5-6. 2p.

Record details

Your Medication Information.

Subjects: *ANTIPSYCHOTIC agents; *DRUG interactions; *DRUG side effects

• Source: Brown University Psychopharmacology Update. Feb2019, Vol. 30 Issue 2, p1-2. 2p.

Record details

Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study.

• Authors : Skryabin, V. Yu.; Vinnikova, M. A.; Ezhkova, E. V.

Subjects: DRUG therapy for schizophrenia; SUBSTANCE abuse; ARIPIPRAZOLE

• Source: Journal of Addictive Diseases. Oct-Dec 2021, Vol. 39 Issue 4, p513-525. 13p.

Record details

Predictors of continuation for asenapine from real-world data in patients with schizophrenia.

• Authors : Takekita, Yoshiteru¹ ; Hiraoka, Shuichi²; Iwama, Yasuhiro²

Subjects: *PATIENT compliance; *DRUG side effects; *LOGISTIC regression analysisJAPAN

• Source: Annals of General Psychiatry. 8/2/2024, Vol. 23 Issue 1, p1-8. 8p.

Record details

Adjunctive cannabidiol shows promise in trial for schizophrenia.

Subjects: *MEDICAL marijuana; *ANTIPSYCHOTIC agents; *CANNABIS (Genus)

• Source: Brown University Psychopharmacology Update. Apr2018, Vol. 29 Issue 4, p3-4. 2p.

Record details

Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.

• Authors : Omi, T.¹ ; Mitsui, Y.²; Matsunaga, H.¹

Subjects: *BROMOCRIPTINE; *BASAL ganglia diseases; *DRUG side effectsJAPAN

• Source: Journal of Clinical Pharmacy & Therapeutics. Feb2018, Vol. 43 Issue 1, p117-120. 4p.

Record details